Table 6.
Serum concentration -median (IQR)- of validated proteins in SSc patients, according to disease duration and organ involvement.
| Early SSc | Long SSc | Cardiomyopathy | PAH | GI | |
|---|---|---|---|---|---|
| Aldolase A | 97.6 (80.5-122) | 83.8 (76.5-93.3) | 87.8 (74.7-92.7) | 132.8 (93.8-172) | 91.9 (78.4-96.0) |
| Ang2 | 1.06 (0.56-1.65)°^ | 1.16 (0.65-3.46)^ | 1.28 (0.62-2.74) | 1.38 (0.57-2.72) | 1.25 (0.63-2.25) |
| BAFFR | 1.08 (0.56-2.43) | 1.05 (0.66-1.78) | 1.25 (0.68-1.72) | 0.94 (0.86-1.01) | 1.36 (0.68-2.43) |
| Calgranulin B | 36.9 (28.1-65.7) | 25.3 (16.6-49.1) | 33.1 (23.1-62.2) | 57.3 (28.1-86.5) | 30.7 (16.6-79.4) |
| Calpain | 13.4 (12.7-14.0) | 13.4 (12.1-14.1) | 13.2 (12.7-13.9) | 12.1 (11.8-12.4) | 13.0 (12.4-13.9) |
| CD177 | 9.13 (6.24-11.3)* | 12.3 (9.34-20.0)* | 14.3 (6.15-19.9) | 5.65 (0-11.3) | 10.8 (6.15-12.4) |
| Eotaxin | 0.91 (0.41-1.18) | 1.01 (0.71-2.64) | 0.80 (0.45-1.35) | 0.85 (0.49-1.21) | 1.16 (0.88-3.12)# |
| Fractalkine | 2.90 (1.35-3.32) | 2.66 (1.62-4.66) | 3.27 (2.85-3.46) | 3.90 (1.85-5.96) | 1.62 (10.8-3.22)# |
| IL-22BP | 26.2 (14.7-60.7) | 26.4 (16.3-50.9) | 28.2 (25.8-54.6) | 28.3 (24.4-56.0) | 27.5 (20.7-50.8) |
| Kininogen | 501 (325-682) | 579 (416-717) | 638 (505-682) | 310 | 591 (508-717) |
| Leptin | 1.63 (0.48-2.93) | 2.76 (0.69-4.81) | 2.12 (1.02-2.65) | 1.43 (0.77-2.09) | 1.63 (0.60-5.45) |
| MMP-12 | 0.07 (0.03-0.10)*°^ | 0.15 (0.09-0.20)*^ | 0.14 (0.09-0.20) | 0.03 | 0.13 (0.09-0.20) |
| TPSB2 | 48.0 (0-151) | 66.2 (31.3-123) | 65.7 (23.0-315) | 71.7 (47.9-151) | 67.9 (38.6-105) |
GI, gastrointestinal involvement; HC, healthy controls; PAH, pulmonary arterial hypertension.
*p < 0.05 comparing early SSc vs. long standing disease.
°p < 0.05 comparing early SSc vs. HC.
^p < 0.05 comparing HC vs. early SSc vs. long standing disease (three-group Kruskal-Wallis).
#p < 0.05 comparing patients with and without gastrointestinal involvement (GI).